Brief: Curasight And Curium Announce Global Partnership For Utrace In Prostate Cancer

Curasight A/S

02/05/2023 04:06

May 1 (Reuters) - Curasight A/S  CURAS.TE :
    * CURASIGHT AND CURIUM ANNOUNCE GLOBAL PARTNERSHIP FOR
UTRACE® IN
PROSTATE CANCER
    * CURASIGHT - CURASIGHT WILL DEVELOP ITS PROPRIETARY UTRACE®
TECHNOLOGY FOR USE IN PROSTATE CANCER UNTIL REGULATORY APPROVAL
IS GRANTED IN EU AND USA
    * CURIUM WILL HAVE RESPONSIBILITY FOR COMMERCIAL MANUFACTURE
OF
UTRACE® AND WORLD-WIDE COMMERCIALIZATION
    * CURASIGHT WILL KEEP ALL RIGHTS TO DEVELOP AND
COMMERCIALIZE
UTRACE IN INDICATIONS OUTSIDE PROSTATE CANCER.
    * CURASIGHT-ELIGIBLE FOR UP TO $70 MN IN DEVELOPMENT AND
COMMERCIAL MILESTONES AS WELL AS DOUBLE-DIGIT ROYALTIES ON SALES
ON EVENTUAL COMMERCIALIZATION

Source text for Eikon:  ID:nPreJDwDva 
Further company coverage:  CURAS.TE 

 ((Reuters.Briefs@thomsonreuters.com;))